These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1186 related items for PubMed ID: 1711560

  • 21. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice.
    Xun C, Brown SA, Jennings CD, Henslee-Downey PJ, Thompson JS.
    Transplantation; 1993 Aug; 56(2):409-17. PubMed ID: 8356598
    [Abstract] [Full Text] [Related]

  • 22. Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon.
    Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trinchieri G.
    J Exp Med; 1985 Nov 01; 162(5):1512-30. PubMed ID: 3932579
    [Abstract] [Full Text] [Related]

  • 23. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
    Baxevanis CN, Gritzapis AD, Papamichail M.
    J Immunol; 2003 Sep 15; 171(6):2953-9. PubMed ID: 12960319
    [Abstract] [Full Text] [Related]

  • 24. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T, Nakamura Y, Takeuchi Y, Tokuda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S.
    J Immunol; 1992 Jan 01; 148(1):285-91. PubMed ID: 1345787
    [Abstract] [Full Text] [Related]

  • 25. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM, Blazar BR, Bach FH, Ochoa AC.
    J Immunol; 1989 Feb 15; 142(4):1383-94. PubMed ID: 2521662
    [Abstract] [Full Text] [Related]

  • 26. Anti-CD3-activated killer T cells: interferon-gamma and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity.
    Fitzpatrick L, Makrigiannis AP, Kaiser M, Hoskin DW.
    J Interferon Cytokine Res; 1996 Jul 15; 16(7):537-46. PubMed ID: 8836920
    [Abstract] [Full Text] [Related]

  • 27. Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.
    Caldera LH, Leon-Ponte M, Acquatella G, Bianco NE, Blanca I.
    Clin Exp Immunol; 1992 Apr 15; 88(1):143-8. PubMed ID: 1373350
    [Abstract] [Full Text] [Related]

  • 28. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ.
    Clin Cancer Res; 1998 Nov 15; 4(11):2859-68. PubMed ID: 9829753
    [Abstract] [Full Text] [Related]

  • 29. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 30. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ.
    Cancer Res; 1989 Jul 15; 49(14):3783-8. PubMed ID: 2472198
    [Abstract] [Full Text] [Related]

  • 31. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
    Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM.
    Blood; 1992 Dec 01; 80(11):2826-34. PubMed ID: 1280479
    [Abstract] [Full Text] [Related]

  • 32. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P, Märten A, Buttgereit P, Weineck S, Scheffold C, Huhn D, Schmidt-Wolf IG.
    J Immunother; 2000 Dec 01; 23(3):304-10. PubMed ID: 10838659
    [Abstract] [Full Text] [Related]

  • 33. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T, Fusauchi Y, Kakui Y, Masuda M, Akahoshi M, Teramura M, Motoji T, Okumura K, Mizoguchi H, Oshimi K.
    Blood; 1993 Mar 01; 81(5):1333-41. PubMed ID: 8095165
    [Abstract] [Full Text] [Related]

  • 34. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.
    Int J Cancer; 2016 Oct 15; 139(8):1799-809. PubMed ID: 27253354
    [Abstract] [Full Text] [Related]

  • 35. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D, Kufer P, Beier I, Sauerbruch T, Schmidt-Wolf IG.
    Cancer Immunol Immunother; 2000 Oct 15; 49(8):441-8. PubMed ID: 11043851
    [Abstract] [Full Text] [Related]

  • 36. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS, Hargrove ME, Ting CC.
    Cancer Res; 1989 Sep 01; 49(17):4770-4. PubMed ID: 2527087
    [Abstract] [Full Text] [Related]

  • 37. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC, Hui KM.
    Leuk Lymphoma; 2003 Sep 01; 44(9):1457-62. PubMed ID: 14565644
    [Abstract] [Full Text] [Related]

  • 38. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells.
    Bensussan A, Lagabrielle JF, Castaigne S, Boisson N, Miclea JM, Benbunan M, Degos L.
    Nouv Rev Fr Hematol (1978); 1989 Sep 01; 31(2):129-32. PubMed ID: 2528119
    [Abstract] [Full Text] [Related]

  • 39. IL-2-dependent generation of natural killer cells from bone marrow: role of MAC-1-, NK1-1- precursors.
    Migliorati G, Moraca R, Nicoletti I, Riccardi C.
    Cell Immunol; 1992 May 01; 141(2):323-31. PubMed ID: 1533568
    [Abstract] [Full Text] [Related]

  • 40. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
    Kedar E, Rezai AR, Giorgi JV, Gale RP, Champlin RE, Mitsuyasu RT, Fahey JL.
    Nat Immun Cell Growth Regul; 1988 May 01; 7(1):13-30. PubMed ID: 2896298
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.